Discover everything you need to know about cell therapies in oncology in our latest Trendline.
Cell therapy technology has become a shining star in oncology, with CAR-T cell therapies transforming standards of care in blood cancers like lymphoma. Building a robust pipeline in oncology is a key strategy to long-term growth for most large pharmas, and many are investing in up-and-coming cell therapies as a future pillar in their cancer care portfolio.
Included in this Trendline:
- Natural killer cells, a rising alternative to CAR-T cell therapy
- Regeneron takes the long-haul approach to oncology, stumbles and all
- After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?
Offered Free by: PharmaVoice and Cardinal Health
See All Resources from: PharmaVoice and Cardinal Health
